NT-proBNP demonstrated promising ability to serve as a prognostic marker for a variety of cardiorenal complications in T2DM. Considering NT-proBNP in clinical assessments could potentially help identify high-risk individuals who may benefit from more intensive therapies. The biomarker improved risk stratification beyond that provided by clinical risk factors alone. The gene discussed is NPPB; the disease is type 2 diabetes mellitus.